Communication: the key piece for empowering teams
Good advice for empowering teams. Communication is at the top of the list in this article, as it should be… https://t.co/9Ejiheh9x6 — 3SixtyPharma (@3SixtyPharma) October 8, 2016
Pharma News
Special Event / Bio-Threat Awareness
On October 12, 2016, the PA BioPharma Networking Group will host an FBI briefing on threat awareness. See event flyer below for more information, including how to register for the event.
$110B market: excessive spending on me-too PD-1 drugs?
Regulator says too many drugmakers chasing same cancer strategy Reuters reports that Dr. Richard Pazdur, who heads the Food and Drug Administration’s office of oncology products, believes that?too many companies are focused on PD-1 inhibitors for?cancer immunotherapy. Whereas PD-1 inhibitors show promise for remarkable efficacy, Dr. Pazdur is reportedly concerned that?too many companies are[…]
Biosimilar switching: new evidence against interchangeability
Biosimilar Switching Not Suitable For All Patients 100% of patients?who developed antibodies to?innovator anti-TNF-? exhibited antibody reactivity against the biosimilar. ?Study results cast?doubt on interchangeability. 8 June 2016 According to a report from European League Against Rheumatism Annual Congress (EULAR) 2016, patients with antibodies to biological infliximab are less likely to benefit from infliximab biosimilar[…]
GI-targeted oral JAK inhibitor shows promise in Phase I Study: TD-1473
Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor TD-1473 showed a reduction in plasma exposure compared to?currently-approved JAK inhibitor. On June 9, 2016, Theravance Biopharma released positive results from a completed Phase I clinical trial of TD-1473, its oral GI-targeted pan-Janus kinase (JAK) inhibitor. TD-1473 is[…]